UBS Group
ARTL icon

UBS Group’s Artelo Biosciences ARTL Stock Holding History

UBS Group’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.14K Buy
+312
New +$8.04K ﹤0.01% 9236
2026
Q1 		– Sell
-1,245
Closed -$41K – 10456
2025
Q4 		$41K Buy
1,245
+1,237
+15,463% +$86.4K ﹤0.01% 7322
2025
Q3 		$959 Buy
8
+5
+167% +$1.38K ﹤0.01% 9482
2025
Q2 		$1.18K Sell
3
-76
-96% -$12.6K ﹤0.01% 9666
2025
Q1 		$11.2K Sell
79
-3
-4% -$543 ﹤0.01% 8566
2024
Q4 		$14.1K Buy
+82
New +$14.8K ﹤0.01% 8112
2024
Q2 		– Sell
-1
Closed -$185 – 9497
2024
Q1 		$185 Buy
+1
New +$239 ﹤0.01% 8748
2023
Q4 		– Sell
-1
Closed -$164 – 9280
2023
Q3 		$164 Buy
+1
New +$300 ﹤0.01% 8758
2023
Q2 		– Sell
-15
Closed -$5.52K – 8882
2023
Q1 		$5.52K Sell
15
-4
-21% -$1.83K ﹤0.01% 8030
2022
Q4 		$8.82K Sell
19
-6
-24% -$2.82K ﹤0.01% 8724
2022
Q3 		$14K Buy
25
+5
+25% +$3.62K ﹤0.01% 7891
2022
Q2 		$16K Buy
20
+12
+150% +$10.6K ﹤0.01% 7171
2022
Q1 		$8K Buy
+8
New +$8.27K ﹤0.01% 8651
2021
Q3 		– Sell
-15
Closed -$43K – 9504
2021
Q2 		$43K Buy
15
+9
+150% +$27.7K ﹤0.01% 6566
2021
Q1 		$26K Buy
+6
New +$23.1K ﹤0.01% 7123
2020
Q2 		– Hold
0
– -$1K – 7918
2020
Q1 		– Hold
0
– – – 7728
2019
Q4 		– Sell
-1
Closed -$8K – 8091
2019
Q3 		$8K Buy
+1
New +$6.86K ﹤0.01% 7263

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

UBS Group's ARTL Position: Q2 2026 in Review

UBS Group opened a new position in Artelo Biosciences (ARTL) in Q2 2026: 312 shares worth $3.14K. The stake represents ﹤0.01% of the portfolio and ranks #9236 among its holdings. This is a return to the name: UBS Group previously reported a position in ARTL as recently as Q4 2025.

UBS Group first reported a position in ARTL in Q3 2019 and has held it in 16 quarters since. The position peaked at $43K in Q2 2021. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • UBS Group held 312 shares of Artelo Biosciences worth $3.14K as of Q2 2026.
  • Artelo Biosciences was a new UBS Group position in Q2 2026.
  • Artelo Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9236 holding.
  • UBS Group first reported a position in Artelo Biosciences in Q3 2019 and has held it in 16 quarters since.
  • UBS Group's Artelo Biosciences position peaked at $43K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.